Skip to main navigation

Company
Science
- Therapeutic Focus
- Scientific References
Pipeline
Clinical Trials
- Clinical Trials Overview
- Expanded Access Policy
Careers
- Job Opportunities
- Our Culture
Investors & Media

Select Page

Press Releases

Press Releases

Year

Jan 16, 2026

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Media & IR Contact

Investor Relations & Media Contact

Steve Forte
Contact Us

Helpful Tools

Print Page
Email Alerts
RSS Feeds

Company

About Us
Leadership
Partnering
Contact

Science

Therapeutic Focus
Scientific References

Pipeline

Development Pipeline
Polθ Inhibitor
RP-1664 PLK4 inhibitor
Camonsertib ATR Inhibitor

Clinical Trials

Clinical Trials Overview
Expanded Access Policy

Careers

Job Opportunities
Our Culture

Investors & Media

Corporate Profile
Press Releases
Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investor Resources

© 2026 Repare Therapeutics

Privacy Policy
Terms of Use
Cookie Policy